Compare BKU & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | CDNA |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | 2010 | 2007 |
| Metric | BKU | CDNA |
|---|---|---|
| Price | $43.04 | $88.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $46.82 | ★ $65.33 |
| AVG Volume (30 Days) | 870.5K | ★ 1.3M |
| Earning Date | 10-21-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 14.61 | N/A |
| EPS | 1.79 | ★ 2.45 |
| Revenue | $21,732,000.00 | ★ $48,324,000.00 |
| Revenue This Year | $3.98 | $30.36 |
| Revenue Next Year | $4.93 | $6.23 |
| P/E Ratio | ★ $24.18 | $33.32 |
| Revenue Growth | 7.45 | ★ 18.93 |
| 52 Week Low | $38.01 | $14.27 |
| 52 Week High | $52.11 | $73.43 |
| Indicator | BKU | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 81.12 |
| Support Level | $41.36 | $17.30 |
| Resistance Level | $43.63 | N/A |
| Average True Range (ATR) | 1.02 | 4.65 |
| MACD | 0.22 | 0.98 |
| Stochastic Oscillator | 66.37 | 88.87 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.